elexacaftor: Clinical Trials

4 trials of elexacaftor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1
Phase 41Completed 1

Follow elexacaftor: new trials by email Literature Review of elexacaftor trials Research Report on elexacaftor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
Trikafta - Non-cystic Fibrosis Bronchiectasis
Phase 4CompletedEmory University322023-04-182026-02-09
Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.
Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening - Cystic Fibrosis
UnknownCHC Montlegia202022-09-012022-10-31
Trikafta in Cystic Fibrosis Patients
Trikafta - Cystic Fibrosis
Phase 2CompletedEmory University422019-09-042026-08-11
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
IVA, TEZ/IVA, VX-445 - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated2252017-01-232022-01-18

Conditions studied

Cystic Fibrosis (3)  ·  Signs and Symptoms, Respiratory (1)

Sponsors

Emory University (2)  ·  CHC Montlegia (1)  ·  Vertex Pharmaceuticals Incorporated (1)

Countries

United States (3)  ·  Belgium (2)  ·  Australia (1)  ·  Netherlands (1)

Top investigators

Eric Sorscher, MD (2)  ·  Patrick Lebecque, PhD (1)

Results publications

PMID 30334692, PMID 33331662, PMID 37983082, PMID 39208836, PMID 39951444, PMID 42271629

NIH funding

2017 (1), R01HL139876 (1)